Impact of Routine Platelet Reactivity Testing with VerifyNow Assay on Antiplatelet Choice After Percutaneous Coronary Intervention
Fakilahyel S Mshelbwala, Daniel W Hugenberg, Rolf P Kreutz Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN, USACorrespondence: Rolf P KreutzKrannert Institute of Cardiology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 4620...
Guardado en:
Autores principales: | Mshelbwala FS, Hugenberg DW, Kreutz RP |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/27a02000a6014ec2bc26522c37139402 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes
por: Gjin Ndrepepa, et al.
Publicado: (2021) -
Recruitment Practices in Multicenter Randomized Clinical Trials: Time for a Relook
por: Prakriti Gaba, et al.
Publicado: (2021) -
Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease
por: Ziwei Xi, et al.
Publicado: (2021) -
Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention
por: Kreutz RP, et al.
Publicado: (2016) -
Infections Deaths in the PLATO Trial
por: Victor Serebruany, et al.
Publicado: (2021)